TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03284983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture spacing for wound closure
Description: The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
Study: NCT03585725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food.
Study: NCT01279044

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
Description: The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard HIV testing with information only
Description: Standard HIV testing with information only
Study: NCT02468440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESPAIR
Description: ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
Study: NCT04887727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crystalline amino acids to assess myofibrillar protein synthesis rates
Description: Amino acid dose = 0.25g/kg bodyweight

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance
Description: Amino acid dose = 0.25g/kg bodyweight
Study: NCT04294459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol) or equivalent
Description: Pharmaceutical form: Tablets~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol) or equivalent
Description: Pharmaceutical form: Tablets~Route of administration: Oral
Study: NCT03720327

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Get FIT
Description: The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get FIT+
Description: The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
Study: NCT03929523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)
Description: In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified).
Study: NCT04294459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous
Study: NCT04553458

Intervention type: DRUG
Intervention: Symptomatic treatment
Description: Symptomatic treatment
Study: NCT03085394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
Study: NCT03929523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic static cold storage
Description: The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
Study: NCT01207284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: strengthening passive and active stretching balance training gait training
Study: NCT03085394

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative intravenous administration of 10 ml saline
Study: NCT00220740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
Description: 2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 25%, United States Pharmacopeia (USP)
Description: Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
Study: NCT03257644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
Study: NCT00692042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1704
Description: One dose, by mouth
Study: NCT02590432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.
Study: NCT04294459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast or equivalent
Description: Pharmaceutical form: Tablets~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast or equivalent
Description: Pharmaceutical form: Tablets~Route of administration: Oral
Study: NCT02479958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: Tooth was isolated using a rubber dam isolation in order to collect the dentin samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: Tooth was isolated using a rubber dam isolation in order to collect the dentin samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: Tooth was isolated using a rubber dam isolation in order to collect the dentin samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth drying
Description: The tooth was dried with air jet.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth drying
Description: The tooth was dried with air jet.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth drying
Description: The tooth was dried with air jet.
Study: NCT01003613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranilast, and Tissucol
Description: 1.0%, 0.1 ml, subconjunctival route, single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beriplast P
Description: 0.1 ml to attach graft
Study: NCT02590432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.
Study: NCT02479958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin wash with chlorhexidine 2%
Description: Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy 1
Description: Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy 2
Description: Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
Study: NCT01607762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
Study: NCT00895778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade with rocuronium and reversal with sugammadex

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular blockade with rocuronium and reversal with sugammadex
Study: NCT01911078

Intervention type: DEVICE
Group type: OTHER
Intervention: EnligHTN™ Renal Denervation System.
Study: NCT03445715

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the wrist joint

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the wrist joint
Study: NCT01267344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, oxaliplatin
Description: GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, gemcitabine, oxaliplatin
Description: E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
Study: NCT01204307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin
Description: The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/cisplatin
Description: The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
Study: NCT05913518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback active
Description: Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurofeedback placebo
Description: Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
Study: NCT02716662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Axona
Description: medical powder, supplement food
Study: NCT02680392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed and Continuous Radiofrequency
Description: Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Block
Description: The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs
Study: NCT03445715

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the wrist joint
Study: NCT00297830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Drug is administered through 5 mg intravenous infusion over 20 minutes
Study: NCT01495364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBS10
Description: dosage = 10 or more million CD34+ cells via intracoronary infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT02590432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.
Study: NCT03825575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Description: A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
Study: NCT03516942

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03326583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer will be orally self-administered by participants.
Study: NCT01551472

Intervention type: DEVICE
Intervention: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
Description: This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
Study: NCT03841526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon RTU Injection With Insulin Pump Reduction
Description: 0.15 mg injection with 50% pump reduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon RTU Injection With Insulin Pump Reduction
Description: 0.15 mg injection with 50% pump reduction
Study: NCT03516942

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04549831

Intervention type: GENETIC
Intervention: Massive parallel sequencing of host genome
Description: Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
Study: NCT03578536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recovery Rapids
Description: This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
Study: NCT03749785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular carbohydrate feeding
Description: 60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single carbohydrate bolus
Description: 60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
Study: NCT03841526

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for Glucagon RTU Injection With Insulin Pump Reduction
Description: vehicle injection with 50% pump reduction
Study: NCT02345720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon - PVP (multi-focal)
Description: The investigational contact lens must be worn at least six hours daily.
Study: NCT01619410

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid 600 mg every 12 hours for 7 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 300 mg po every 6 hours for 7 days
Study: NCT00643188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of atrial fibrillation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.